SkinBioTherapeutics (LON:SBTX) Trading Down 23.1% – Should You Sell?

SkinBioTherapeutics plc (LON:SBTX) shares fell 23.1% on Friday . The stock traded as low as GBX 12.77 and last traded at GBX 15. 2,636,007 shares were traded during mid-day trading, an increase of 80% from the average session volume of 1,466,438 shares. The stock had previously closed at GBX 19.50.

SkinBioTherapeutics Stock Down 36.6%

The stock’s 50-day moving average price is GBX 17.21 and its 200-day moving average price is GBX 16.14. The company has a current ratio of 0.93, a quick ratio of 10.01 and a debt-to-equity ratio of 27.57. The company has a market cap of £32.01 million, a P/E ratio of -39.88 and a beta of 2.01.

SkinBioTherapeutics (LON:SBTX) last posted its quarterly earnings data on Monday, December 8th. The company reported GBX (0.31) EPS for the quarter. SkinBioTherapeutics had a negative net margin of 237.95% and a negative return on equity of 115.86%.

About SkinBioTherapeutics

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.